Vanita Noronha1, Amit Joshi1, Shalaka Marfatia2, Vijay Patil1, Shashikant Juvekar3, Supreeta Arya3, Shripad Banavali1, Kumar Prabhash4. 1. Department of Medical Oncology, Tata Memorial Hospital, Room no-304, Parel, Mumbai, 400012, India. 2. pharmEDGE, Mumbai, India. 3. Department of Radiology, Tata Memorial Hospital, Mumbai, India. 4. Department of Medical Oncology, Tata Memorial Hospital, Room no-304, Parel, Mumbai, 400012, India. kumarprabhashtmh@gmail.com.
Abstract
OBJECTIVE: The objective of this study was to evaluate changes in health related quality of life (HRQoL) in patients with metastatic head and neck (H&N) cancer randomized to receive metronomic (methotrexate and celecoxib) or cisplatin chemotherapy. METHODS:Patients older than 18 years, with a Karnofsky Performance score of ≥70, and diagnosed with metastatic, locally advanced inoperable or recurrent head and neck (H&N) cancer not amenable to surgery or radiation were randomized (1:1) to receive metronomic or cisplatin chemotherapy. All patients were recruited from the Tata Memorial Hospital, Mumbai, India. In addition to demographic and baseline clinical characteristics, patients were asked to rate their HRQoL using the EORTC QLQ-C30 and the EORTC QLQ-H&N35 questionnaires (Indian versions) at baseline and at the end of each chemo cycle (every 3 weeks) till the end of study or early termination. RESULTS: Of the 110 patients screened, 87 agreed to participate in the study. Mean age of the study population was 47.5 years (S.D. ±10.04) for the metronomic group and 47.2 years (S.D. ±9.89) for the cisplatin group. Overall quality of life was not significantly different between the two treatment groups from baseline to end of treatment. However, there was a statistically significant improvement in Pain QLQ-C30 score from baseline to week 3 (OR = 3.14, p = 0.036) and week 6 (OR = 3.33, p = 0.034) in the metronomic arm compared with the cisplatin arm. CONCLUSION: In addition to improvements in survival, understanding the impact of treatment options on changes in HRQoL is important as it can aid physicians in making treatment and rehabilitation decisions for patients with advanced inoperable H&N cancer.
RCT Entities:
OBJECTIVE: The objective of this study was to evaluate changes in health related quality of life (HRQoL) in patients with metastatic head and neck (H&N) cancer randomized to receive metronomic (methotrexate and celecoxib) or cisplatin chemotherapy. METHODS:Patients older than 18 years, with a Karnofsky Performance score of ≥70, and diagnosed with metastatic, locally advanced inoperable or recurrent head and neck (H&N) cancer not amenable to surgery or radiation were randomized (1:1) to receive metronomic or cisplatin chemotherapy. All patients were recruited from the Tata Memorial Hospital, Mumbai, India. In addition to demographic and baseline clinical characteristics, patients were asked to rate their HRQoL using the EORTC QLQ-C30 and the EORTC QLQ-H&N35 questionnaires (Indian versions) at baseline and at the end of each chemo cycle (every 3 weeks) till the end of study or early termination. RESULTS: Of the 110 patients screened, 87 agreed to participate in the study. Mean age of the study population was 47.5 years (S.D. ±10.04) for the metronomic group and 47.2 years (S.D. ±9.89) for the cisplatin group. Overall quality of life was not significantly different between the two treatment groups from baseline to end of treatment. However, there was a statistically significant improvement in Pain QLQ-C30 score from baseline to week 3 (OR = 3.14, p = 0.036) and week 6 (OR = 3.33, p = 0.034) in the metronomic arm compared with the cisplatin arm. CONCLUSION: In addition to improvements in survival, understanding the impact of treatment options on changes in HRQoL is important as it can aid physicians in making treatment and rehabilitation decisions for patients with advanced inoperable H&N cancer.
Entities:
Keywords:
EORTC QLQ-C30; EORTC QLQ-H&N35; Head and neck cancer; Health-related quality of life; Outcome assessments; Validation
Authors: R J Amdur; J T Parsons; W M Mendenhall; R R Million; S P Stringer; N J Cassisi Journal: Int J Radiat Oncol Biol Phys Date: 1989-01 Impact factor: 7.038
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Yu-Ning Wong; Brian L Egleston; Kush Sachdeva; Naa Eghan; Melanie Pirollo; Tammy K Stump; John Robert Beck; Katrina Armstrong; Jerome Sanford Schwartz; Neal J Meropol Journal: Med Care Date: 2013-09 Impact factor: 2.983
Authors: Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: Avinash Pandey; A Desai; V Ostwal; V Patil; A Kulkarni; R Kulkarni; N Patil; D Chaukar; K Prabhash; Shripad D Banavali Journal: South Asian J Cancer Date: 2016 Apr-Jun
Authors: Arnold Degboe; Sarah L Knight; Katarina Halling; Andrew Trigg; Tamara Al-Zubeidi; Natalie Aldhouse; Helen Kitchen; Lori Wirth; Simon N Rogers Journal: J Patient Rep Outcomes Date: 2018-08-01